Novo Nordisk ADR [NVO] stock is trading at $51.47, down -1.77%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The NVO shares have gain 7.03% over the last week, with a monthly amount glided 5.67%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Novo Nordisk ADR [NYSE: NVO] stock has seen the most recent analyst activity on December 08, 2025, when Argus downgraded its rating to a Hold. On October 01, 2025, upgrade upgraded it’s rating to Buy. Morgan Stanley downgraded its rating to an Underweight but stick to its price target of $47 on September 29, 2025. Berenberg upgraded its rating to a Buy. Rothschild & Co Redburn upgraded its rating to Buy for this stock on September 16, 2025. In a note dated September 09, 2025, Bernstein upgraded an Outperform rating on this stock.
Novo Nordisk ADR [NVO] stock has fluctuated between $43.08 and $93.80 over the past year. Currently, Wall Street analysts expect the stock to reach $47.5 within the next 12 months. Novo Nordisk ADR [NYSE: NVO] shares were valued at $51.47 at the most recent close of the market. An investor can expect a potential drop of -7.71% based on the average NVO price forecast.
Analyzing the NVO fundamentals
Novo Nordisk ADR [NYSE:NVO] reported sales of 46.69B for the trailing twelve months, which represents a growth of 11.80%. Gross Profit Margin for this corporation currently stands at 0.84% with Operating Profit Margin at 0.46%, Pretax Profit Margin comes in at 0.45%, and Net Profit Margin reading is 0.36%. To continue investigating profitability, this company’s Return on Assets is posted at 0.23, Equity is 0.78 and Total Capital is 0.52. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.59.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 51.21 points at the first support level, and at 50.96 for the second support level. However, for the 1st resistance point, the stock is sitting at 51.86, and for the 2nd resistance point, it is at 52.25.
Ratios To Look Out For
For context, Novo Nordisk ADR’s Current Ratio is 0.78. Also, the Quick Ratio is 0.57, while the Cash Ratio stands at 0.09. Considering the valuation of this stock, the price to sales ratio is 3.71, the price to book ratio is 8.55 and price to earnings (TTM) ratio is 14.99.
Transactions by insiders
Recent insider trading involved Novo Nordisk A/S, 10% Owner, that happened on May 30 ’25 when 0.92 million shares were purchased.
